Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

It works on the mechanism of inhibiting IL-4 and IL-13-two dominant cytokines that produce inflammation. By selectively inhibiting these cytokines, Dupixent decreases inflammation ... of 3.15% during ...

Get Instant Summarized Text (Gist) Asthma and antibiotic use at the time of initial endoscopic sinus surgery increase the likelihood of nasal polyp recurrence, necessitating revision surgery. Age ...

The frequency of polyp diagnoses in close relatives was strongly associated with colorectal cancer risk. Polyp history in second-degree relatives was only influential with multiple polyp diagnoses.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Polyps in the gallbladder may not cause any symptoms. Depending on the type of polyps, they can be benign, be a sign of inflammation, or potentially lead to cancer. Polyps are abnormal tissue ...

and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to drive increased sales of Dupixent, which is approved for a range of ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

The CEO discussed the success of Dupixent and the remarkable achievement ... their excitement about the progress of anti-OX40L mechanism of action. Overall, the positive outcomes from the clinical ...